ibd patients could be silent carriers for novel coronavirus and less prone to its severe adverse events: true or false?

Inflammatory bowel diseases (ibds) are chronic disorders of the gastrointestinal tract. the goal of ibd treatment is to reduce the inflammation period and induce long-term remission. use of anti-inflammatory drugs including corticosteroids, immunosuppressants and biologicals, is often the first step in the treatment of ibd. therefore, ibd patients in pandemic of infectious diseases are considered a high-risk group. the public believes that ibd patients are at a higher risk in the current coronavirus 2 pandemic. nevertheless, these patients may experience mild or moderate complications compared to healthy people. this might be because of particular anti-tnf-α treatment or any immunosuppressant that ibd patients receive. moreover, these patients might be silent carrier for the virus.